Related Experiment Videos
Fatal hemolysis caused by ceftriaxone
1Department of Pediatrics, Albany Medical College, New York.
The Journal of Pediatrics
|May 1, 1995
Summary
A boy with leukemia died from severe hemolysis after receiving intravenous ceftriaxone. This fatal immune reaction highlights a critical risk associated with this common antibiotic in vulnerable patients.
Area of Science:
- Hematology
- Pharmacology
- Immunology
Background:
- Ceftriaxone is a widely used third-generation cephalosporin antibiotic.
- Patients with hematological malignancies may have altered immune responses and increased susceptibility to adverse drug reactions.
Observation:
- A pediatric patient with leukemia experienced sudden, massive hemolysis following intravenous administration of ceftriaxone.
- The fatal outcome was initially not attributed to the antibiotic.
Findings:
- Retrospective analysis and comparison with a similar reported case confirmed immune-mediated hemolysis as the cause of death.
- The adverse event was linked to intravenous ceftriaxone administration.
Implications:
- Clinicians should be aware of the potential for severe, immune-mediated hemolytic anemia associated with ceftriaxone, particularly in immunocompromised patients.
- This case underscores the importance of considering drug-induced hemolysis in patients presenting with unexplained anemia or hemolysis, especially after antibiotic exposure.
- Further investigation into the immunogenic mechanisms of ceftriaxone may be warranted to identify at-risk populations and prevent similar fatal events.